Drug Profile
Research programme: peptide therapeutics - PreveCeutical Medical/UniQuest
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator PreveCeutical Medical; UniQuest
- Class Analgesics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Pain in Australia
- 28 Sep 2021 No recent reports of development identified for research development in Pain in Canada
- 08 Aug 2017 PreveCeutical and UniQuest enter into a research and development agreement for peptide therapeutics